Large-scale data on the hepatitis D virus (HDV)/hepatitis B virus (HBV) co-infection rate is needed to estimate the current ...
A Phase 2 clinical trial finds that ALT flares are common in hepatitis D patients treated with pegylated interferon-alpha, ...
Hosted on MSN9mon
Vir Biotechnology (VIR) Up on Positive Data From HDV StudyImage Source: Zacks Investment Research The company’s current clinical development pipeline consists of candidates targeting HDV, hepatitis B virus (HBV) and human immunodeficiency virus (HIV).
Gilead Sciences has been knocked back in its quest to bring the first drug therapy for hepatitis D virus (HDV) to the US market, after the FDA rejected its marketing application. News of the ...
The proceeds are earmarked mainly for trials of BJT-778, its lead candidate for chronic hepatitis D virus (HDV) infections, but will also support earlier-stage hepatitis B virus (HBV) projects ...
GlobalData on MSN18d
Vir enrols first subject in Phase III programme to assess CHD therapyCHD is said to occur due to the hepatitis delta virus (HDV), leading to cirrhosis and liver failure within five years for ...
Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback